A Phase 2 double blinded, randomised, placebo controlled dose-finding study to evaluate the safety tolerability and efficacy of Volixibat potassium an apical sodium-dependant bile acid transport inhibitor (ASBTi) in adults with non-alcoholic steatohepatitis (NASH) (SHIRE Study)

1st February 2017 - ongoing

Status:

Specialism: Liver.